Strong Q4 and full year at Biogen Idec as pipeline continues to cause concern
This article was originally published in Scrip
Executive Summary
The fourth quarter was "a good finish to a very good year", said Biogen Idec's CEO Dr George Scangos. Net profit fell by 21% to $240 million, or 99 cents a share, due to restructuring, but excluding one-time items, the company earned $1.42 a share, or $347 million.